Skandinaviska Enskilda Banken AB publ Buys 529,529 Shares of Boston Scientific Corporation $BSX

Skandinaviska Enskilda Banken AB publ lifted its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 26.1% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 2,554,682 shares of the medical equipment provider’s stock after acquiring an additional 529,529 shares during the quarter. Boston Scientific comprises approximately 1.0% of Skandinaviska Enskilda Banken AB publ’s holdings, making the stock its 15th largest position. Skandinaviska Enskilda Banken AB publ owned about 0.17% of Boston Scientific worth $249,414,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Vanguard Group Inc. boosted its position in Boston Scientific by 0.8% during the third quarter. Vanguard Group Inc. now owns 138,249,447 shares of the medical equipment provider’s stock worth $13,497,294,000 after purchasing an additional 1,115,337 shares during the period. State Street Corp lifted its stake in shares of Boston Scientific by 1.1% in the second quarter. State Street Corp now owns 65,191,864 shares of the medical equipment provider’s stock worth $7,002,258,000 after buying an additional 713,379 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Boston Scientific by 2.0% in the second quarter. Geode Capital Management LLC now owns 32,424,982 shares of the medical equipment provider’s stock worth $3,466,320,000 after buying an additional 622,602 shares during the last quarter. Norges Bank bought a new stake in shares of Boston Scientific during the 2nd quarter worth $2,089,937,000. Finally, Invesco Ltd. grew its stake in Boston Scientific by 1.4% in the 2nd quarter. Invesco Ltd. now owns 16,851,518 shares of the medical equipment provider’s stock valued at $1,810,022,000 after buying an additional 226,578 shares during the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.

Analyst Ratings Changes

A number of research firms have issued reports on BSX. Truist Financial decreased their price target on shares of Boston Scientific from $120.00 to $95.00 and set a “buy” rating for the company in a report on Thursday, February 5th. Barclays decreased their target price on Boston Scientific from $136.00 to $124.00 and set an “overweight” rating for the company in a research note on Tuesday, February 3rd. JPMorgan Chase & Co. dropped their price target on Boston Scientific from $135.00 to $100.00 and set an “overweight” rating on the stock in a research report on Thursday, February 5th. Stifel Nicolaus reduced their price objective on Boston Scientific from $125.00 to $110.00 and set a “buy” rating for the company in a research report on Wednesday, February 4th. Finally, Robert W. Baird dropped their target price on shares of Boston Scientific from $118.00 to $101.00 and set an “outperform” rating on the stock in a research report on Thursday, February 5th. One research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $109.43.

Insider Transactions at Boston Scientific

In other Boston Scientific news, CEO Michael F. Mahoney sold 160,901 shares of the company’s stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the sale, the chief executive officer directly owned 1,411,735 shares of the company’s stock, valued at approximately $131,983,105.15. This represents a 10.23% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Arthur C. Butcher sold 17,313 shares of Boston Scientific stock in a transaction that occurred on Monday, December 1st. The shares were sold at an average price of $101.55, for a total transaction of $1,758,135.15. Following the completion of the transaction, the executive vice president owned 23,600 shares of the company’s stock, valued at $2,396,580. This trade represents a 42.32% decrease in their position. The disclosure for this sale is available in the SEC filing. 0.50% of the stock is owned by insiders.

Boston Scientific Trading Up 0.8%

BSX stock opened at $74.72 on Tuesday. Boston Scientific Corporation has a 1-year low of $72.69 and a 1-year high of $109.50. The company has a current ratio of 1.51, a quick ratio of 0.96 and a debt-to-equity ratio of 0.47. The business’s 50 day moving average is $90.56 and its 200-day moving average is $97.35. The firm has a market cap of $110.76 billion, a P/E ratio of 38.51, a P/E/G ratio of 1.03 and a beta of 0.67.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 EPS for the quarter, beating the consensus estimate of $0.78 by $0.02. The business had revenue of $5.29 billion for the quarter, compared to analyst estimates of $5.29 billion. Boston Scientific had a return on equity of 19.96% and a net margin of 14.44%.Boston Scientific’s quarterly revenue was up 15.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.70 EPS. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. Equities analysts anticipate that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.